These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35694192)

  • 1. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
    Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
    Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody.
    Gong Y; Germeraad WTV; Zhang X; Wu N; Li B; Janssen L; He Z; Gijbels MJJ; Wu B; Gijsbers BLMG; Olieslagers TI; Bos GMJ; Zheng L; Klein Wolterink RGJ
    Mol Ther; 2024 Aug; 32(8):2711-2727. PubMed ID: 38943249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.
    Bexte T; Albinger N; Al Ajami A; Wendel P; Buchinger L; Gessner A; Alzubi J; Särchen V; Vogler M; Rasheed HM; Jung BA; Wolf S; Bhayadia R; Oellerich T; Klusmann JH; Penack O; Möker N; Cathomen T; Rieger MA; Imkeller K; Ullrich E
    Nat Commun; 2024 Sep; 15(1):8439. PubMed ID: 39349459
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
    Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
    Kamiya T; Seow SV; Wong D; Robinson M; Campana D
    J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergized regulation of NK cell education by NKG2A and specific Ly49 family members.
    Zhang X; Feng J; Chen S; Yang H; Dong Z
    Nat Commun; 2019 Nov; 10(1):5010. PubMed ID: 31676749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
    Huang RS; Lai MC; Lin S
    Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.
    Tognarelli S; Wirsching S; von Metzler I; Rais B; Jacobs B; Serve H; Bader P; Ullrich E
    Front Immunol; 2018; 9():2743. PubMed ID: 30542346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-free CRISPR knock-in of a chimeric antigen receptor into
    Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
    Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
    Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
    Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permanent silencing of NKG2A expression for cell-based therapeutics.
    Figueiredo C; Seltsam A; Blasczyk R
    J Mol Med (Berl); 2009 Feb; 87(2):199-210. PubMed ID: 19002424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling
    Mahaweni NM; Ehlers FAI; Bos GMJ; Wieten L
    Front Immunol; 2018; 9():2848. PubMed ID: 30564241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.
    Hò GT; Celik AA; Huyton T; Hiemisch W; Blasczyk R; Simper GS; Bade-Doeding C
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis.
    Park KS; Park JH; Song YW
    Tissue Antigens; 2008 Oct; 72(4):342-6. PubMed ID: 18700876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.
    Hussein BA; Kristenson L; Pesce S; Wöhr A; Tian Y; Hallner A; Brune M; Hellstrand K; Tang KW; Bernson E; Thorén FB
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.